The total planned enrollment across all breast cancer CAR-T trials exceeds 1,000 patients, with major trials including NCT04650451 (HER2, n = 220) [164], NCT02414269 (mesothelin, n = 179) [165], and NCT04025216 (TnMUC1, n = 112). Here, ERBB2 is linked to breast cancer.